董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Scott Morrison | 男 | Independent Director | 68 | 6.46万美元 | 未持股 | 2025-06-26 |
| Yujiro Hata | 男 | Director, President and Chief Executive Officer | 51 | 226.27万美元 | 未持股 | 2025-06-26 |
| Terry Rosen | 男 | Chairman | 65 | 4.24万美元 | 未持股 | 2025-06-26 |
| Wendy L. Yarno | -- | Independent Director | -- | 未披露 | 未持股 | 2025-06-26 |
| Malcolm Garret Hampton | -- | Independent Director | -- | 未披露 | 未持股 | 2025-06-26 |
| Catherine J. Mackey | -- | Independent Director | -- | 未披露 | 未持股 | 2025-06-26 |
| Jeffrey Stein | 男 | Independent Director | 70 | 4.24万美元 | 未持股 | 2025-06-26 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Yujiro Hata | 男 | Director, President and Chief Executive Officer | 51 | 226.27万美元 | 未持股 | 2025-06-26 |
| Stuart Dorman | -- | Chief Commercial Officer | -- | 未披露 | 未持股 | 2025-06-26 |
| Michael Anthony White | -- | Chief Scientific Officer | -- | 未披露 | 未持股 | 2025-06-26 |
| Darrin M. Beaupre | -- | Chief Medical Officer | -- | 未披露 | 未持股 | 2025-06-26 |
| Joshua Bleharski | -- | Chief Financial Officer | -- | 未披露 | 未持股 | 2025-06-26 |
| Andres Ruiz Briseno | -- | Principal Accounting Officer, Senior Vice President, Head of Finance and Investor Relations | -- | 未披露 | 未持股 | 2025-06-26 |
董事简历
中英对照 | 中文 | 英文- Scott Morrison
-
Scott Morrison自2020年4月起在Vera Therapeutics, Inc.董事会任职。从1996年到2015年12月，莫里森先生是一家公共会计师事务所Ernst & Young LLP的合伙人，他还在2002年至2015年12月期间担任美国生命科学领域的负责人。Morrison先生自2015年12月起担任生物制药公司IDEAYA生物科学的董事会成员，自2018年7月起担任生物技术公司TERM1 Biosciences，Inc.，一家生物技术公司，自2015年12月起担任Audentes Therapeutics, Inc.，一家生物技术公司，自2021年1月15日起通过将其出售给Astellas Pharma Inc.自2015年12月起担任生物制药公司全球血液疗法公司，自2020年10月起担任生物技术公司Escape Bio，Inc.的董事会成员。莫里森先生还曾在许多其他生命科学行业组织的董事会任职。莫里森此前曾在生命科学基金会、加州生命科学协会、生物技术研究所和生物技术创新组织新兴公司部门的董事会任职。他拥有加州大学伯克利分校的工商管理学士学位，是一名注册会计师，非在职。
Scott Morrison,has served on Board since April 2020. From 1996 to December 2015, Mr. Morrison was a partner with Ernst & Young LLP, a public accounting firm, where he also served as U.S. Life Sciences Leader from 2002 to December 2015. Mr. Morrison has served on the board of directors of Corvus Pharmaceuticals Inc.(Nasdaq: CRVS), a biopharmaceutical company, since December 2015, IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a biotechnology company, since July 2018, Audentes Therapeutics, Inc., a biotechnology company, from December 2015 through its sale to Astellas Pharma Inc. on January 15, 2021, Global Blood Therapeutics, Inc., a biopharmaceutical company, from December 2015 through its sale to Pfizer on October 4, 2022, Zai Lab Limited (Nasdaq: ZLAB), a biotechnology company, since October 2021, Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS), a biotechnology company, since October 2022 and Escape Bio, Inc., a biotechnology company, from July 2020 to November 2022. Mr. Morrison has also held roles on the boards of directors of numerous other life sciences industry organizations. Mr. Morrison has previously served on the boards of directors of the Life Sciences Foundation, the California Life Sciences Association, the Biotech Institute and the Emerging Companies Section of the Biotechnology Innovation Organization. He holds a B.S. in Business Administration from the University of California, Berkeley and is a certified public accountant (inactive). - Scott Morrison自2020年4月起在Vera Therapeutics, Inc.董事会任职。从1996年到2015年12月，莫里森先生是一家公共会计师事务所Ernst & Young LLP的合伙人，他还在2002年至2015年12月期间担任美国生命科学领域的负责人。Morrison先生自2015年12月起担任生物制药公司IDEAYA生物科学的董事会成员，自2018年7月起担任生物技术公司TERM1 Biosciences，Inc.，一家生物技术公司，自2015年12月起担任Audentes Therapeutics, Inc.，一家生物技术公司，自2021年1月15日起通过将其出售给Astellas Pharma Inc.自2015年12月起担任生物制药公司全球血液疗法公司，自2020年10月起担任生物技术公司Escape Bio，Inc.的董事会成员。莫里森先生还曾在许多其他生命科学行业组织的董事会任职。莫里森此前曾在生命科学基金会、加州生命科学协会、生物技术研究所和生物技术创新组织新兴公司部门的董事会任职。他拥有加州大学伯克利分校的工商管理学士学位，是一名注册会计师，非在职。
- Scott Morrison,has served on Board since April 2020. From 1996 to December 2015, Mr. Morrison was a partner with Ernst & Young LLP, a public accounting firm, where he also served as U.S. Life Sciences Leader from 2002 to December 2015. Mr. Morrison has served on the board of directors of Corvus Pharmaceuticals Inc.(Nasdaq: CRVS), a biopharmaceutical company, since December 2015, IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a biotechnology company, since July 2018, Audentes Therapeutics, Inc., a biotechnology company, from December 2015 through its sale to Astellas Pharma Inc. on January 15, 2021, Global Blood Therapeutics, Inc., a biopharmaceutical company, from December 2015 through its sale to Pfizer on October 4, 2022, Zai Lab Limited (Nasdaq: ZLAB), a biotechnology company, since October 2021, Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS), a biotechnology company, since October 2022 and Escape Bio, Inc., a biotechnology company, from July 2020 to November 2022. Mr. Morrison has also held roles on the boards of directors of numerous other life sciences industry organizations. Mr. Morrison has previously served on the boards of directors of the Life Sciences Foundation, the California Life Sciences Association, the Biotech Institute and the Emerging Companies Section of the Biotechnology Innovation Organization. He holds a B.S. in Business Administration from the University of California, Berkeley and is a certified public accountant (inactive).
- Yujiro Hata
-
Yujiro Hata，自2015年6月起担任董事会成员、总裁兼首席执行官。他创立了IDEAYA Biosciences， Inc.，担任其第一位员工兼首席执行官，同时从2015年到2018年担任风险投资公司5AM Ventures的驻场高管。从2014年到2015年8月，他担任Flexus Biosciences， Inc.（或Flexus）和FLX Bio， Inc.（或FLX Bio）的首席运营官，这两家公司都是免疫肿瘤学公司，他作为初创公司加入，并于2015年4月领导Flexus被Bristol-Myers Squibb Co.（或Bristol-Myers Squibb）收购。从2010年到Amgen Inc.（或Amgen Inc.）于2013年10月收购，他担任Onyx Pharmaceuticals， Inc.的企业发展和战略副总裁，在那里他担任战略和战略资产管理主管，以及交易主管。从2002年到2010年，他担任Enanta Pharmaceuticals， Inc.的副总裁、业务发展高级副总裁和首席商务官。他曾在麦肯锡公司、ImClone系统公司和哥伦比亚医学院任职。他是Xencor， Inc.的董事会成员。他获得The Wharton School at The University of Pennsylvania的工商管理硕士学位和Colorado College的化学学士学位。
Yujiro Hata has served as a member of board of directors and as President and Chief Executive Officer since June 2015. He launched IDEAYA Biosciences, Inc. as its first employee and Chief Executive Officer, while serving as an Executive-in-Residence at 5AM Ventures, a venture capital firm, from 2015 to 2018. From 2014 to August 2015 he served as Chief Operating Officer at Flexus Biosciences, Inc., or Flexus, and FLX Bio, Inc., or FLX Bio, both immuno-oncology companies, which he joined as startups and led through Flexus' acquisition by Bristol-Myers Squibb Co., or Bristol-Myers Squibb, in April 2015. From 2010 until its acquisition by Amgen Inc., or Amgen, in October 2013 he was Vice President, Corporate Development and Strategy at Onyx Pharmaceuticals, Inc. where he served as Head of Strategy and Strategic Asset Management, and Head of Transactions. From 2002 to 2010 Mr. Hata served as Vice President and Senior Vice President of Business Development, and Chief Business Officer at Enanta Pharmaceuticals, Inc. He earlier served in roles at McKinsey & Company, ImClone Systems Incorporated, and Columbia Medical School. He serves on the board of directors at Xencor, Inc. Mr. Hata obtained an M.B.A. at The Wharton School at the University of Pennsylvania and a B.A. in Chemistry from Colorado College. - Yujiro Hata，自2015年6月起担任董事会成员、总裁兼首席执行官。他创立了IDEAYA Biosciences， Inc.，担任其第一位员工兼首席执行官，同时从2015年到2018年担任风险投资公司5AM Ventures的驻场高管。从2014年到2015年8月，他担任Flexus Biosciences， Inc.（或Flexus）和FLX Bio， Inc.（或FLX Bio）的首席运营官，这两家公司都是免疫肿瘤学公司，他作为初创公司加入，并于2015年4月领导Flexus被Bristol-Myers Squibb Co.（或Bristol-Myers Squibb）收购。从2010年到Amgen Inc.（或Amgen Inc.）于2013年10月收购，他担任Onyx Pharmaceuticals， Inc.的企业发展和战略副总裁，在那里他担任战略和战略资产管理主管，以及交易主管。从2002年到2010年，他担任Enanta Pharmaceuticals， Inc.的副总裁、业务发展高级副总裁和首席商务官。他曾在麦肯锡公司、ImClone系统公司和哥伦比亚医学院任职。他是Xencor， Inc.的董事会成员。他获得The Wharton School at The University of Pennsylvania的工商管理硕士学位和Colorado College的化学学士学位。
- Yujiro Hata has served as a member of board of directors and as President and Chief Executive Officer since June 2015. He launched IDEAYA Biosciences, Inc. as its first employee and Chief Executive Officer, while serving as an Executive-in-Residence at 5AM Ventures, a venture capital firm, from 2015 to 2018. From 2014 to August 2015 he served as Chief Operating Officer at Flexus Biosciences, Inc., or Flexus, and FLX Bio, Inc., or FLX Bio, both immuno-oncology companies, which he joined as startups and led through Flexus' acquisition by Bristol-Myers Squibb Co., or Bristol-Myers Squibb, in April 2015. From 2010 until its acquisition by Amgen Inc., or Amgen, in October 2013 he was Vice President, Corporate Development and Strategy at Onyx Pharmaceuticals, Inc. where he served as Head of Strategy and Strategic Asset Management, and Head of Transactions. From 2002 to 2010 Mr. Hata served as Vice President and Senior Vice President of Business Development, and Chief Business Officer at Enanta Pharmaceuticals, Inc. He earlier served in roles at McKinsey & Company, ImClone Systems Incorporated, and Columbia Medical School. He serves on the board of directors at Xencor, Inc. Mr. Hata obtained an M.B.A. at The Wharton School at the University of Pennsylvania and a B.A. in Chemistry from Colorado College.
- Terry Rosen
-
Terry Rosen自2016年1月以来一直担任我们的董事会成员。Rosen博士分别自2015年4月和2015年5月起担任生物制药公司ArcusBiosciences，Inc.的董事会成员和首席执行官。他还于2016年11月至2017年12月担任生物制药公司Pact Pharma，Inc.或Pact Pharma的首席执行官。Rosen博士于2015年4月短暂担任FLX Bio的首席执行官。此前，Rosen博士从2013年10月到2015年4月Flexus被百时美施贵宝（Bristol-Myers Squibb）收购共同创立并担任其首席执行官。在此之前，Rosen博士于2004年8月至2013年1月在Amgen工作，最近于2011年11月至2013年1月担任Therapeutic Discovery Vice President。他还曾于1993年10月至2004年8月在Tularik Inc.工作，该公司于1987年12月至1993年9月被辉瑞公司（Pfizer）的中央研究部门Amgen收购，1985年7月至1987年12月被雅培公司收购。Rosen博士拥有加州大学伯克利分校（University of California，Berkeley）的化学博士学位和密歇根大学（University of Michigan）的化学学士学位。
Terry Rosen has served as a member of board of directors since January 2016. Dr. Rosen has served on the board of directors and as the Chief Executive Officer of Arcus Biosciences, Inc., a biopharmaceutical company, since April 2015 and May 2015 respectively. He also served as the Chief Executive Officer of PACT Pharma, Inc., or PACT Pharma, a biopharmaceutical company, from November 2016 to December 2017. Dr. Rosen served briefly in April 2015 as the Chief Executive Officer of FLX Bio. Previously, Dr. Rosen co-founded and served as the Chief Executive Officer of Flexus from October 2013 to April 2015 when it was acquired by Bristol-Myers Squibb. Prior to that, Dr. Rosen was at Amgen from August 2004 to January 2013 where he most recently served as Vice President of Therapeutic Discovery from November 2011 to January 2013. He also worked at Tularik Inc., from October 1993 to August 2004 when it was acquired by Amgen, the Central Research division of Pfizer Inc., or Pfizer, from December 1987 to September 1993 and Abbott Laboratories, from July 1985 to December 1987. Dr. Rosen holds a Ph.D. in Chemistry from the University of California, Berkeley and a B.S. in Chemistry from the University of Michigan. - Terry Rosen自2016年1月以来一直担任我们的董事会成员。Rosen博士分别自2015年4月和2015年5月起担任生物制药公司ArcusBiosciences，Inc.的董事会成员和首席执行官。他还于2016年11月至2017年12月担任生物制药公司Pact Pharma，Inc.或Pact Pharma的首席执行官。Rosen博士于2015年4月短暂担任FLX Bio的首席执行官。此前，Rosen博士从2013年10月到2015年4月Flexus被百时美施贵宝（Bristol-Myers Squibb）收购共同创立并担任其首席执行官。在此之前，Rosen博士于2004年8月至2013年1月在Amgen工作，最近于2011年11月至2013年1月担任Therapeutic Discovery Vice President。他还曾于1993年10月至2004年8月在Tularik Inc.工作，该公司于1987年12月至1993年9月被辉瑞公司（Pfizer）的中央研究部门Amgen收购，1985年7月至1987年12月被雅培公司收购。Rosen博士拥有加州大学伯克利分校（University of California，Berkeley）的化学博士学位和密歇根大学（University of Michigan）的化学学士学位。
- Terry Rosen has served as a member of board of directors since January 2016. Dr. Rosen has served on the board of directors and as the Chief Executive Officer of Arcus Biosciences, Inc., a biopharmaceutical company, since April 2015 and May 2015 respectively. He also served as the Chief Executive Officer of PACT Pharma, Inc., or PACT Pharma, a biopharmaceutical company, from November 2016 to December 2017. Dr. Rosen served briefly in April 2015 as the Chief Executive Officer of FLX Bio. Previously, Dr. Rosen co-founded and served as the Chief Executive Officer of Flexus from October 2013 to April 2015 when it was acquired by Bristol-Myers Squibb. Prior to that, Dr. Rosen was at Amgen from August 2004 to January 2013 where he most recently served as Vice President of Therapeutic Discovery from November 2011 to January 2013. He also worked at Tularik Inc., from October 1993 to August 2004 when it was acquired by Amgen, the Central Research division of Pfizer Inc., or Pfizer, from December 1987 to September 1993 and Abbott Laboratories, from July 1985 to December 1987. Dr. Rosen holds a Ph.D. in Chemistry from the University of California, Berkeley and a B.S. in Chemistry from the University of Michigan.
- Wendy L. Yarno
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Malcolm Garret Hampton
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Catherine J. Mackey
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Jeffrey Stein
-
Jeffrey Stein，自2014年10月起在Paratek Pharmaceuticals, Inc.董事会任职，并于2022年12月被任命为Paratek Pharmaceuticals, Inc.首席独立董事。Stein博士自2014年起担任Cidara Therapeutics, Inc.（Cidara）的总裁、首席执行官兼董事。在加入Cidara之前，Stein博士是Trius Therapeutics，Inc.的首席执行官，从2007年创立到2013年9月被Cubist Pharmaceuticals收购。Stein博士也是抗生素工作组的创始主席和总裁，该工作组是行业领先的501（c）（6）组织。除了在Cidara和Paratek的董事会任职外，Stein博士目前还是Ideaya Biosciences，Inc.的董事，并在圣地亚哥Life Science Cares的管理委员会任职。此前，Stein博士是Sofinnova Ventures的风险合伙人和Kauffman研究员，并于2005年开设了该公司的圣地亚哥办事处。在加入Sofinnova Ventures之前，Stein博士是Quorex Pharmaceuticals，Inc.的联合创始人兼首席科学官，该公司于2005年被辉瑞制药公司收购。他还曾在Diversa公司和Agouron研究所担任首席科学家。Stein博士在加州理工学院作为Alexander Hollaender杰出博士后研究员开展了博士后研究，并在加州大学圣地亚哥分校作为NASA研究生研究员开展了研究生工作。
Jeffrey Stein,has served on Paratek Pharmaceuticals, Inc. Board since October 2014 and was appointed as Paratek Pharmaceuticals, Inc. Lead Independent Director in December 2022. Dr. Stein has been the President, Chief Executive Officer and Director of Cidara Therapeutics, Inc., or Cidara, since 2014. Prior to joining Cidara, Dr. Stein was Chief Executive Officer of Trius Therapeutics, Inc. from its founding in 2007 until its acquisition by Cubist Pharmaceuticals in September 2013. Dr. Stein is also founding Chairman and President of the Antibiotics Working Group, an industry leading 501(c)(6) organization. In addition to serving on the boards of Cidara and Paratek, Dr. Stein is currently a director of Ideaya Biosciences, Inc. and serves on the board of managers of Life Science Cares, San Diego. Previously, Dr. Stein was a Venture Partner and Kauffman Fellow with Sofinnova Ventures and opened the firm's San Diego office in 2005. Prior to joining Sofinnova Ventures, Dr. Stein was co-founder and Chief Scientific Officer of Quorex Pharmaceuticals, Inc. which was acquired by Pfizer Pharmaceuticals in 2005. He has also served as a Principal Scientist with Diversa Corporation and the Agouron Institute. Dr. Stein conducted his postdoctoral research as an Alexander Hollaender Distinguished Postdoctoral Fellow at the California Institute of Technology and his graduate work as a NASA Graduate Student Researcher Fellow at the University of California, San Diego. - Jeffrey Stein，自2014年10月起在Paratek Pharmaceuticals, Inc.董事会任职，并于2022年12月被任命为Paratek Pharmaceuticals, Inc.首席独立董事。Stein博士自2014年起担任Cidara Therapeutics, Inc.（Cidara）的总裁、首席执行官兼董事。在加入Cidara之前，Stein博士是Trius Therapeutics，Inc.的首席执行官，从2007年创立到2013年9月被Cubist Pharmaceuticals收购。Stein博士也是抗生素工作组的创始主席和总裁，该工作组是行业领先的501（c）（6）组织。除了在Cidara和Paratek的董事会任职外，Stein博士目前还是Ideaya Biosciences，Inc.的董事，并在圣地亚哥Life Science Cares的管理委员会任职。此前，Stein博士是Sofinnova Ventures的风险合伙人和Kauffman研究员，并于2005年开设了该公司的圣地亚哥办事处。在加入Sofinnova Ventures之前，Stein博士是Quorex Pharmaceuticals，Inc.的联合创始人兼首席科学官，该公司于2005年被辉瑞制药公司收购。他还曾在Diversa公司和Agouron研究所担任首席科学家。Stein博士在加州理工学院作为Alexander Hollaender杰出博士后研究员开展了博士后研究，并在加州大学圣地亚哥分校作为NASA研究生研究员开展了研究生工作。
- Jeffrey Stein,has served on Paratek Pharmaceuticals, Inc. Board since October 2014 and was appointed as Paratek Pharmaceuticals, Inc. Lead Independent Director in December 2022. Dr. Stein has been the President, Chief Executive Officer and Director of Cidara Therapeutics, Inc., or Cidara, since 2014. Prior to joining Cidara, Dr. Stein was Chief Executive Officer of Trius Therapeutics, Inc. from its founding in 2007 until its acquisition by Cubist Pharmaceuticals in September 2013. Dr. Stein is also founding Chairman and President of the Antibiotics Working Group, an industry leading 501(c)(6) organization. In addition to serving on the boards of Cidara and Paratek, Dr. Stein is currently a director of Ideaya Biosciences, Inc. and serves on the board of managers of Life Science Cares, San Diego. Previously, Dr. Stein was a Venture Partner and Kauffman Fellow with Sofinnova Ventures and opened the firm's San Diego office in 2005. Prior to joining Sofinnova Ventures, Dr. Stein was co-founder and Chief Scientific Officer of Quorex Pharmaceuticals, Inc. which was acquired by Pfizer Pharmaceuticals in 2005. He has also served as a Principal Scientist with Diversa Corporation and the Agouron Institute. Dr. Stein conducted his postdoctoral research as an Alexander Hollaender Distinguished Postdoctoral Fellow at the California Institute of Technology and his graduate work as a NASA Graduate Student Researcher Fellow at the University of California, San Diego.
高管简历
中英对照 | 中文 | 英文- Yujiro Hata
Yujiro Hata，自2015年6月起担任董事会成员、总裁兼首席执行官。他创立了IDEAYA Biosciences， Inc.，担任其第一位员工兼首席执行官，同时从2015年到2018年担任风险投资公司5AM Ventures的驻场高管。从2014年到2015年8月，他担任Flexus Biosciences， Inc.（或Flexus）和FLX Bio， Inc.（或FLX Bio）的首席运营官，这两家公司都是免疫肿瘤学公司，他作为初创公司加入，并于2015年4月领导Flexus被Bristol-Myers Squibb Co.（或Bristol-Myers Squibb）收购。从2010年到Amgen Inc.（或Amgen Inc.）于2013年10月收购，他担任Onyx Pharmaceuticals， Inc.的企业发展和战略副总裁，在那里他担任战略和战略资产管理主管，以及交易主管。从2002年到2010年，他担任Enanta Pharmaceuticals， Inc.的副总裁、业务发展高级副总裁和首席商务官。他曾在麦肯锡公司、ImClone系统公司和哥伦比亚医学院任职。他是Xencor， Inc.的董事会成员。他获得The Wharton School at The University of Pennsylvania的工商管理硕士学位和Colorado College的化学学士学位。
Yujiro Hata has served as a member of board of directors and as President and Chief Executive Officer since June 2015. He launched IDEAYA Biosciences, Inc. as its first employee and Chief Executive Officer, while serving as an Executive-in-Residence at 5AM Ventures, a venture capital firm, from 2015 to 2018. From 2014 to August 2015 he served as Chief Operating Officer at Flexus Biosciences, Inc., or Flexus, and FLX Bio, Inc., or FLX Bio, both immuno-oncology companies, which he joined as startups and led through Flexus' acquisition by Bristol-Myers Squibb Co., or Bristol-Myers Squibb, in April 2015. From 2010 until its acquisition by Amgen Inc., or Amgen, in October 2013 he was Vice President, Corporate Development and Strategy at Onyx Pharmaceuticals, Inc. where he served as Head of Strategy and Strategic Asset Management, and Head of Transactions. From 2002 to 2010 Mr. Hata served as Vice President and Senior Vice President of Business Development, and Chief Business Officer at Enanta Pharmaceuticals, Inc. He earlier served in roles at McKinsey & Company, ImClone Systems Incorporated, and Columbia Medical School. He serves on the board of directors at Xencor, Inc. Mr. Hata obtained an M.B.A. at The Wharton School at the University of Pennsylvania and a B.A. in Chemistry from Colorado College.- Yujiro Hata，自2015年6月起担任董事会成员、总裁兼首席执行官。他创立了IDEAYA Biosciences， Inc.，担任其第一位员工兼首席执行官，同时从2015年到2018年担任风险投资公司5AM Ventures的驻场高管。从2014年到2015年8月，他担任Flexus Biosciences， Inc.（或Flexus）和FLX Bio， Inc.（或FLX Bio）的首席运营官，这两家公司都是免疫肿瘤学公司，他作为初创公司加入，并于2015年4月领导Flexus被Bristol-Myers Squibb Co.（或Bristol-Myers Squibb）收购。从2010年到Amgen Inc.（或Amgen Inc.）于2013年10月收购，他担任Onyx Pharmaceuticals， Inc.的企业发展和战略副总裁，在那里他担任战略和战略资产管理主管，以及交易主管。从2002年到2010年，他担任Enanta Pharmaceuticals， Inc.的副总裁、业务发展高级副总裁和首席商务官。他曾在麦肯锡公司、ImClone系统公司和哥伦比亚医学院任职。他是Xencor， Inc.的董事会成员。他获得The Wharton School at The University of Pennsylvania的工商管理硕士学位和Colorado College的化学学士学位。
- Yujiro Hata has served as a member of board of directors and as President and Chief Executive Officer since June 2015. He launched IDEAYA Biosciences, Inc. as its first employee and Chief Executive Officer, while serving as an Executive-in-Residence at 5AM Ventures, a venture capital firm, from 2015 to 2018. From 2014 to August 2015 he served as Chief Operating Officer at Flexus Biosciences, Inc., or Flexus, and FLX Bio, Inc., or FLX Bio, both immuno-oncology companies, which he joined as startups and led through Flexus' acquisition by Bristol-Myers Squibb Co., or Bristol-Myers Squibb, in April 2015. From 2010 until its acquisition by Amgen Inc., or Amgen, in October 2013 he was Vice President, Corporate Development and Strategy at Onyx Pharmaceuticals, Inc. where he served as Head of Strategy and Strategic Asset Management, and Head of Transactions. From 2002 to 2010 Mr. Hata served as Vice President and Senior Vice President of Business Development, and Chief Business Officer at Enanta Pharmaceuticals, Inc. He earlier served in roles at McKinsey & Company, ImClone Systems Incorporated, and Columbia Medical School. He serves on the board of directors at Xencor, Inc. Mr. Hata obtained an M.B.A. at The Wharton School at the University of Pennsylvania and a B.A. in Chemistry from Colorado College.
- Stuart Dorman
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Michael Anthony White
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Darrin M. Beaupre
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Joshua Bleharski
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Andres Ruiz Briseno
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介